← back to search

Nirav Malani

LabCorp (United States) · US
Area of research
Molecular Biology · Genetics
Research interest
Research interests include CRISPR and Genetic Engineering, Virus-based gene therapy research, HIV Research and Treatment, and HIV/AIDS drug development and treatment.
h-index
39
citations
6,618
works
67
NIH funding
primary concept
Biology
email

Recent publications

Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention
Science 2020cited by 652position: middledoi
Apolipoprotein L-1 renal risk variants form active channels at the plasma membrane driving cytotoxicity
eLife 2020cited by 76position: middledoi
INSPIIRED: A Pipeline for Quantitative Analysis of Sites of New DNA Integration in Cellular Genomes
Molecular Therapy — Methods & Clinical Development 2016cited by 135position: middledoi
INSPIIRED: Quantification and Visualization Tools for Analyzing Integration Site Distributions
Molecular Therapy — Methods & Clinical Development 2016cited by 93position: middledoi
A Modified γ-Retrovirus Vector for X-Linked Severe Combined Immunodeficiency
New England Journal of Medicine 2014cited by 410position: middledoi
<i>piggyBac</i> transposase tools for genome engineering
Proceedings of the National Academy of Sciences 2013cited by 229position: middledoi
The BET Family of Proteins Targets Moloney Murine Leukemia Virus Integration near Transcription Start Sites
Cell Reports 2013cited by 177position: middledoi
HIV latency and integration site placement in five cell-based models
Retrovirology 2013cited by 115position: middledoi
HRP-2 determines HIV-1 integration site selection in LEDGF/p75 depleted cells
Retrovirology 2012cited by 67position: middledoi
A resurrected mammalian <i>hAT</i> transposable element and a closely related insect element are highly active in human cell culture
Proceedings of the National Academy of Sciences 2012cited by 65position: middledoi
Comparative Analysis of the Recently Discovered hAT Transposon TcBuster in Human Cells
PLoS ONE 2012cited by 48position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Frederic D. Bushman · Translational Therapeutics (United States)8 papers (2012–2016)Charles C. Berry · University of California San Diego3 papers (2013–2016)Nancy L. Craig · HOPE Clinic3 papers (2012–2013)Xianghong Li · Qingdao University3 papers (2012–2013) · 2 papers (2016–2016)Laure Caccavelli · Hôpital Necker-Enfants Malades2 papers (2016–2016)Rik Gijsbers · KU Leuven2 papers (2012–2013) · 2 papers (2016–2016)Christopher L. Nobles · Exact Sciences (United States)2 papers (2016–2016)Sofie Vets · KU Leuven2 papers (2012–2013)Zeger Debyser · KU Leuven2 papers (2012–2013)Paul Bates · Translational Therapeutics (United States)2 papers (2016–2016)Aubrey Bailey · Ferring Pharmaceuticals (Switzerland)2 papers (2016–2016)Peter W. Atkinson · University of California, Riverside2 papers (2012–2012)Kyle Bittinger · Intercept Pharmaceuticals (United States)2 papers (2016–2016) · 2 papers (2016–2016) · 2 papers (2016–2016) · 2 papers (2016–2016)Salima Hacein‐Bey‐Abina · Centre National de la Recherche Scientifique2 papers (2016–2016)Jan De Rijck · KU Leuven2 papers (2012–2013)